Beijing Tiantan Biological Products Co., Ltd.
600161
Rangering i aksjer
#4320
Beijing Tiantan Biological Products Co., Ltd., established in 1998 and... Beijing Tiantan Biological Products Co., Ltd., established in 1998 and headquartered in Beijing, China, is actively involved in the full spectrum of blood product operations within China. This includes pioneering research and development, manufacturing, sales, and providing consultancy services. Its comprehensive product line features critical blood-derived medicines such as intravenous immunoglobulin, human albumin, and various specialized human immunoglobulins for conditions like hepatitis B (both standard and freeze-dried formulations) and tetanus, alongside other general human immunoglobulin preparations and intravenous blood system solutions. The company operates as a subsidiary of China National Biotec Group Company Limited.
Aksjekurs
$1.81
Markedsverdi
$3.59B
Endring (1 dag)
-0.90%
Endring (1 år)
-32.39%
Land
CN
Handel Beijing Tiantan Biological Products Co., Ltd. (600161)
Kategori
Healthcare
Inntekter for Beijing Tiantan Biological Products Co., Ltd. (600161)
Inntekter i 2026 TTM: 0
Ifølge Beijing Tiantan Biological Products Co., Ltd. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Beijing Tiantan Biological Products Co., Ltd. fra 2001 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2025 | $260.52M | -25.35% |
| 2024 | $348.98M | 37.34% |
| 2023 | $254.09M | 22.89% |
| 2022 | $206.77M | 5.90% |
| 2021 | $195.25M | 15.45% |
| 2020 | $169.13M | 12.87% |
| 2019 | $149.85M | 18.76% |
| 2018 | $126.18M | -46.94% |
| 2017 | $237.80M | 345.91% |
| 2016 | $53.33M | 74.97% |
| 2015 | $30.48M | -37.81% |
| 2014 | $49.01M | -45.63% |
| 2013 | $90.14M | 26.29% |
| 2012 | $71.38M | 31.58% |
| 2011 | $54.25M | 32.45% |
| 2010 | $40.96M | -20.34% |
| 2009 | $51.42M | 51.23% |
| 2008 | $34.00M | 38.09% |
| 2007 | $24.62M | 53.52% |
| 2006 | $16.04M | 54.94% |
| 2005 | $10.35M | 53.69% |
| 2004 | $6.73M | 8.91% |
| 2003 | $6.18M | 14.01% |
| 2002 | $5.42M | 10.09% |
| 2001 | $4.93M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
